Nutra Pharma Company Description
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States.
The company offers Nyloxin, an over-the-counter (OTC) pain reliever; Nyloxin Extra Strength, a non-narcotic and non-addictive treatment for severe pain; Pet Pain-Away, an OTC pain reliver for dogs and cats; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxury Feet, an OTC pain reliever for foot pain from high heels and stilettos.
It is also involved in developing RPI-78M to treat neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, and general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain.
The company was incorporated in 2000 and is based in Boca Raton, Florida.
| Country | United States |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Michael Flax |
Contact Details
Address: 6400 Park of Commerce Blvd Boca Raton, Florida 33487 United States | |
| Phone | 954 509 0911 |
| Website | nutrapharma.com |
Stock Details
| Ticker Symbol | NPHC |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US67060U2087 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael D. Flax D.D.S., M.S., P.A. | Chief Executive Officer, Chief Financial Officer and Chairman |
| Dr. Dale Vander Putten MBA, Ph.D. | Chief Scientific Officer |
| Joe Lucas | Vice President of Operations |
| Nina Goldstein | Secretary |